Stockscreener 앱 받기
6.85
2.00%
-0.14
시장 영업 전:
7.51
0.66
+9.64%
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics evaluates strategic options amid advancements - Investing.com
Tempest Announces Plan to Explore Strategic Alternatives to - GlobeNewswire
Tempest Therapeutics announces 1-for-13 reverse stock split - Investing.com Australia
Tempest Therapeutics announces 1-for-13 reverse stock split By Investing.com - Investing.com Canada
Tempest Therapeutics Announced 1-For-13 Reverse Stock Split - marketscreener.com
TPST stock touches 52-week low at $0.69 amid market challenges - Investing.com Canada
TPST stock touches 52-week low at $0.69 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest Update - Defense World
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Virtu Financial LLC Purchases Shares of 43,105 Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
What is HC Wainwright’s Estimate for TPST Q1 Earnings? - Defense World
FY2028 Earnings Estimate for TPST Issued By William Blair - Defense World
0.39%
3.66%
자본화:
|
볼륨(24시간):